Protagonist Therapeutics, Inc.
PTGX
$44.27
-$1.00-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -83.40% | 3,550.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -83.40% | 3,550.01% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -83.40% | 3,550.01% | |||
| SG&A Expenses | 31.09% | -11.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.60% | -4.92% | |||
| Operating Income | -115.23% | 405.84% | |||
| Income Before Tax | -108.72% | 497.45% | |||
| Income Tax Expenses | -- | 573.81% | |||
| Earnings from Continuing Operations | -108.85% | 496.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -108.85% | 496.49% | |||
| EBIT | -115.23% | 405.84% | |||
| EBITDA | -115.03% | 407.84% | |||
| EPS Basic | -108.76% | 492.90% | |||
| Normalized Basic EPS | -108.63% | 493.86% | |||
| EPS Diluted | -109.57% | 467.65% | |||
| Normalized Diluted EPS | -109.20% | 469.67% | |||
| Average Basic Shares Outstanding | 1.02% | 0.91% | |||
| Average Diluted Shares Outstanding | -5.18% | 7.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||